Adam Maeder analyst PIPER SANDLER

Currently out of the existing stock ratings of Adam Maeder, 213 are a BUY (71.48%), 78 are a HOLD (26.17%), 7 are a SELL (2.35%).

Adam Maeder

Work Performance Price Targets & Ratings Chart

Analyst Adam Maeder, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 62.44% that have a potential upside of 34.43% achieved within 122 days.

Adam Maeder’s has documented 599 price targets and ratings displayed on 23 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on RMD, ResMed at 02-Feb-2026.

Wall Street Analyst Adam Maeder

Analyst best performing recommendations are on RBOT (VICARIOUS SURGICAL).
The best stock recommendation documented was for TCMD (TACTILE SYSTEMS TECHNOLOGY) at 11/4/2025. The price target of $20 was fulfilled within 1 day with a profit of $4.23 (26.82%) receiving and performance score of 268.23.

Average potential price target upside

APEN Apollo Endosurgery AXNX Axonics Modulation Technologies EW Edwards Lifesciences Corp INSP Inspire Medical Systems ISRG Intuitive Surgical LIVN LivaNova PLC NVRO Nevro Corp SILK Silk Road Medical STIM Neuronetics STXS Stereotaxis SWAV Shockwave Medical TCMD Tactile Systems Technology XENT Intersect ENT NYXH Nyxoah ZYXI Zynex RBOT Vicarious Surgical NARI Inari Medical  NSPR InspireMD ABT Abbott Laboratories M Macy’s RMD ResMed RXST Rxsight TMDI Titan Medical

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 23-Jan-2023

$10

$13

3 years 18 days ago
(23-Jan-2023)

1/2 (50%)

$0.16 (1.63%)

70

Hold Since 04-Jan-2023

$10

$10

3 years 1 months 7 days ago
(04-Jan-2023)

5/6 (83.33%)

$0.12 (1.21%)

167

Hold Since 30-Nov-2022

$10

$14

3 years 2 months 12 days ago
(30-Nov-2022)

1/5 (20%)

$-0.13 (-1.28%)

13

Buy Since 08-Sep-2021

$9

$-1 (-10.00%)

$13

3 years 9 months 7 days ago
(04-May-2022)

1/3 (33.33%)

$3.44 (61.87%)

209

Buy Since 18-Nov-2019

$12

$2 (20.00%)

$14

3 years 11 months 19 days ago
(23-Feb-2022)

9/13 (69.23%)

$6.64 (123.88%)

124

Show more analysts

Please expand the browser size to see the chart

Which stock is Adam Maeder is most bullish on?

Potential upside of $106.85 has been obtained for ISRG (INTUITIVE SURGICAL)

Which stock is Adam Maeder is most reserved on?

Potential downside of $2.61 has been obtained for RXST (RXSIGHT)

What Year was the first public recommendation made by Adam Maeder?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?